ABSTRACT
Endobronchial valves (EBVs) are a novel, minimally invasive bronchoscopic management technique for persistent air leaks that fail conservative therapy. Currently, 2 EBVs are available in the United States: the Spiration Valve System (Olympus, Redmond, WA) and the Zephyr Valve (Pulmonx, Redwood, CA). These valves are Food and Drug Administration-approved to reduce hyperinflation in emphysematous patients via bronchoscopic lung-volume reduction. However, more recently, the Spiration Valve has been granted a compassionate use exemption through the Food and Drug Administration for persistent postsurgical air leaks. Despite their popularity, these devices are not free from side effects. As an anesthesiologist, it is vital to be aware of the pathophysiology of this patient population so that safe and effective anesthetics may be provided during valve placement. Here, the use of EBVs is discussed in a patient who presented with a persistent air leak after a transthoracic needle aspiration that failed treatment due to persistent hypoxemia, warranting EBV removal.
Subject(s)
Pneumothorax , Humans , Pneumothorax/etiology , Bronchoscopy/methods , Prostheses and Implants , Pneumonectomy/adverse effects , Hypoxia/etiology , Hypoxia/surgery , Treatment OutcomeABSTRACT
BACKGROUND: Floppy mitral valve/mitral valve prolapse (FMV/MVP), a heritable disorder of connective tissue, often leads to mitral regurgitation (MR) and is the most common cause for mitral valve surgery in developed countries. Connective tissue disorders may affect aortic function, and a stiff aorta may increase the severity of MR. Aortic function, however, has not been studied in FMV/MVP with MR. METHODS: A total of 17 patients (11 men, 6 women) with FMV/MVP and significant MR were compared with 20 controls matched for age and gender. Aortic diameters (AoD) were measured from left ventriculograms at 2 and 4 cm above the aortic valve. Aortic pressures were measured directly using fluid-filled catheters. Aortic distensibility was calculated using the formula: 2(systolic AoD-diastolic AoD)/(diastolic AoD x pulse pressure). RESULTS: Aortic distensibility was significantly lower in FMV/MVP compared with control at 2 cm above the aortic valve (1.00 ± 0.19 versus 3.78 ± 1.10 10-3 mm Hg-1, respectively; p = 0.027) and 4 cm above the aortic valve (0.89 ± 0.16 versus 3.22 ± 0.19 10-3 mm Hg-1, respectively; p = 0.007). FMV/MVP patients had greater left ventricular (LV) end-systolic (88 ± 72 mL versus 35 ± 15 mL, p = 0.002) and end-diastolic (165 ± 89 mL versus 100 ± 41 mL, p = 0.005) volumes, and lower LV ejection fraction, compared with control (50 ± 12% versus 57 ± 6%, p = 0.034). CONCLUSION: Aortic distensibility is decreased (consistent with a stiff aorta) in patients with FMV/MVP and MR. A stiff aorta may increase the severity of MR. Thus, abnormal aortic function, which also deteriorates with age, may play an important role in the natural history of MR due to FMV/MVP.